| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/13/2002 | WO2002028270A3 The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor |
| 06/13/2002 | WO2002026929A3 Kini-3 motor protein and methods for its use |
| 06/13/2002 | WO2002019996A3 Prevention of acute sinusitis and sinus attack |
| 06/13/2002 | WO2002017857A3 Methods and compositions for inhibiting angiogenesis |
| 06/13/2002 | WO2002015891A3 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| 06/13/2002 | WO2002014357A3 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 06/13/2002 | WO2002012339A3 Sequences for integrin alpha-8 |
| 06/13/2002 | WO2002007712A3 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 06/13/2002 | WO2001098350A3 Compositions comprising net-4 modulations and their use for treating neoplastic disease |
| 06/13/2002 | WO2001098277A3 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 06/13/2002 | WO2001097618A3 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites |
| 06/13/2002 | WO2001095884A3 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 06/13/2002 | WO2001094547A3 Molecular delivery vehicle for delivery of selected compounds to targets |
| 06/13/2002 | WO2001090159A3 Compositions and methods for delivery of a molecule into a cell |
| 06/13/2002 | WO2001089554A3 Treatment of acute coronary syndrome with glp-1 |
| 06/13/2002 | WO2001087981A3 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 06/13/2002 | WO2001085257A3 Opioid antagonist compositions and dosage forms |
| 06/13/2002 | WO2001085145A3 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 06/13/2002 | WO2001083550A3 Gpr22 modulators as appetite-control agents |
| 06/13/2002 | WO2001079170A3 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |
| 06/13/2002 | WO2001076577A3 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| 06/13/2002 | WO2001072721A3 Synergistic methods and compositions for treating cancer |
| 06/13/2002 | WO2001062237A3 Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| 06/13/2002 | WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 06/13/2002 | WO2001057242A3 Methods of protein destabilization and uses thereof |
| 06/13/2002 | WO2001035942A3 Analgesic compositions containing buprenorphine |
| 06/13/2002 | WO2001029256A3 Cephalic pain susceptibility marker |
| 06/13/2002 | WO2000037022A3 Combination therapy for the treatment of sepsis |
| 06/13/2002 | US20020072592 Nucleotide sequences which code anticarcinogenic agent for use in the treatment mammary gland cancer |
| 06/13/2002 | US20020072540 For therapy, prophylaxis and diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with deficiency of lung surfactant |
| 06/13/2002 | US20020072539 For therapy of tumor necrosis factor(TNF), edema, neurological deficits, stroke and for therapy of pathological conditions caused by TNF-alpha |
| 06/13/2002 | US20020072538 NMDA NR2B antagonists for treatment |
| 06/13/2002 | US20020072534 20- Hete antagonists and agonists |
| 06/13/2002 | US20020072505 Such as enprofylline (3-propylxanthine) and MRS 1220; asthma |
| 06/13/2002 | US20020072491 Homology to members of the myosin light chain kinase subfamily |
| 06/13/2002 | US20020072488 Amino acid sequences of human transporter peptides and proteins that are related to the sugar transporter subfamily; identifying modulators of the transporter peptides |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020072119 Preventing tumor growth; obtain cells, transform with expression vector, monitor cells for reduction in cell proliferation |
| 06/13/2002 | US20020072115 Pancreatic islet cell growth factors |
| 06/13/2002 | US20020072101 Novel human nucleic acid molecules and polypeptides encoding cation channels |
| 06/13/2002 | US20020072090 Hr-1 receptor |
| 06/13/2002 | US20020072083 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
| 06/13/2002 | US20020071872 Laxative composition |
| 06/13/2002 | US20020071857 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 06/13/2002 | US20020071846 Vaccines comprising oil bodies |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | US20020071832 Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| 06/13/2002 | US20020071829 Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| 06/13/2002 | CA2436856A1 Immunomodulatory constructs and their uses |
| 06/13/2002 | CA2436847A1 Treatment of cancer by reduction of intracellular energy and pyrimidines |
| 06/13/2002 | CA2436732A1 Protein modification and maintenance molecules |
| 06/13/2002 | CA2436666A1 Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 06/13/2002 | CA2436662A1 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | CA2436311A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 06/13/2002 | CA2431861A1 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 06/13/2002 | CA2431203A1 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | CA2431202A1 Human sprouty-4 polypeptide |
| 06/13/2002 | CA2431005A1 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis |
| 06/13/2002 | CA2430993A1 G-protein coupled receptors |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430951A1 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | CA2430712A1 Schizophrenia-related voltage-gated ion channel gene and protein |
| 06/13/2002 | CA2430624A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 06/13/2002 | CA2430536A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/13/2002 | CA2430524A1 Human transporter proteins, nucleic acid molecules encoding them,and uses thereof |
| 06/13/2002 | CA2430379A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/13/2002 | CA2430376A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2430191A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2428390A1 Enzymes |
| 06/13/2002 | CA2428208A1 Lipid-associated molecules |
| 06/13/2002 | CA2428092A1 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | CA2427430A1 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 06/13/2002 | CA2426988A1 Multicomponent compositions containing chitosan and methods of preparing same |
| 06/13/2002 | CA2425396A1 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 06/13/2002 | CA2363575A1 Crystal structure |
| 06/12/2002 | EP1213300A1 Novel human androgen receptor variants |
| 06/12/2002 | EP1213031A2 Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist |
| 06/12/2002 | EP1213028A1 Hm1.24 antigen expression potentiators |
| 06/12/2002 | EP1213020A2 Pharmaceutical compositions having appetite suppressant activity |
| 06/12/2002 | EP1213019A2 Method for treating chronic obstructive pulmonary disease |
| 06/12/2002 | EP1213018A1 Preventive and therapeutic agents for eye diseases |
| 06/12/2002 | EP1213015A1 Oral pharmaceutical composition with delayed release of proton pump inhibitors |
| 06/12/2002 | EP1212941A2 Modulating ramp activity |
| 06/12/2002 | EP1212621A1 Screening for agents modulating tgf-beta cell signalling |
| 06/12/2002 | EP1212616A2 Inhibitors of binding between proteins and macromolecular ligands |
| 06/12/2002 | EP1212464A2 Diagnostics and therapeutics for osteoporosis |
| 06/12/2002 | EP1212453A1 Method to identify gene function using small molecule probes |
| 06/12/2002 | EP1212436A2 Protein phosphatase and kinase proteins |
| 06/12/2002 | EP1212433A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 06/12/2002 | EP1212428A1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression |
| 06/12/2002 | EP1212421A1 Gas1 polypeptides |
| 06/12/2002 | EP1212417A2 Interleukin-1-receptor associated kinase-3 (irak3) |
| 06/12/2002 | EP1212413A1 A transmembrane trap for isolating membrane bound proteins |
| 06/12/2002 | EP1212410A2 Dna encoding the human serine protease eos |
| 06/12/2002 | EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212366A2 Therapeutic compounds comprised of anti-fc receptor binding agents |